Balancing Clinically Meaningful Weight Loss with Placebo-Like Tolerability: Phase II Lessons from Petrelintide

• Evaluate how once-weekly petrelintide achieved up to 10.7% mean weight loss at 42 weeks while maintaining a tolerability profile comparable to placebo, demonstrating the potential for selective amylin agonism to deliver sustained efficacy without the gastrointestinal burden commonly associated with obesity therapies
• Examine how four-week dose escalation supported high maintenance-dose attainment, minimal nausea after titration and no vomiting at the maximally effective dose, providing practical insight into how dosing strategy can optimize adherence and the efficacy–tolerability balance
• Explore how sex-based differences, body-composition outcomes and petrelintide’s fibrillation-resistant design can inform Phase III development and combination strategy, enabling developers to identify responsive populations and position amylin as both a differentiated monotherapy and a complementary partner to other metabolic mechanisms

Speakers: